Alectinib
- Generic Name
- Alectinib
- Brand Names
- Alecensa, Alecensaro
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34N4O2
- CAS Number
- 1256580-46-7
- Unique Ingredient Identifier
- LIJ4CT1Z3Y
- Background
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ...
- Indication
Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this ...
- Associated Conditions
- Refractory, metastatic Non small cell lung cancer
- Associated Therapies
- -
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Instituto Nacional de Cancerologia de Mexico
- Target Recruit Count
- 41
- Registration Number
- NCT03779191
- Locations
- 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Mexico
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Conditions
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03768063
- Locations
- 🇺🇸
Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States
🇺🇸HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT03737994
- Locations
- 🇺🇸
Miller-Dwan Hospital, Duluth, Minnesota, United States
🇺🇸Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸Grady Memorial Hospital, Delaware, Ohio, United States
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 248
- Registration Number
- NCT03596866
- Locations
- 🇦🇷
Sanatorio Duarte Quiros, Cordoba, Argentina
🇨🇳Peking Union Medical College Hospital - East, Beijing, Beijing, China
🇨🇱Centro de Investigacion Clinica Bradford Hill, Recoleta, Santiago, Chile
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 111
- Registration Number
- NCT03546894
- Locations
- 🇺🇸
EmpiraMed, Inc., Maynard, Massachusetts, United States
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Conditions
- Interventions
- Drug: AlectinibDrug: VismodegibDrug: IpatasertibDrug: CarboplatinDrug: OlaparibDrug: ErlotinibDrug: CisplatinDrug: BevacizumabDrug: GemcitabineDrug: VemurafenibDrug: CobimetinibDrug: Trastuzumab Subcutaneous (SC)Drug: PertuzumabDrug: AtezolizumabDrug: PaclitaxelDrug: EntrectinibDrug: IvosidenibDrug: Pemigatinib
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT03498521
- Locations
- 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇦🇺Blacktown Hospital, Blacktown, New South Wales, Australia
🇫🇮Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 14
- Registration Number
- NCT03445000
- Locations
- 🇳🇱
University Medical Center Maastricht, Maastricht, Netherlands
🇳🇱The Netherlands Cancer Institute Amsterdam, Amsterdam, Netherlands
🇨🇭Hôpital Universitaire de Genève, Genève, Switzerland
Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 355
- Registration Number
- NCT03271554
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT03202940
- Locations
- 🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT03194893
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States
🇺🇸Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States
🇨🇳Guangdong General Hospital, Guangzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.